Takeda reported that zasocitinib, its TYK2 inhibitor acquired in a multibillion‑dollar deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said more than half of treated patients achieved clear or almost clear skin after four months and will file regulatory submissions during fiscal 2026. Takeda positioned the oral TYK2 candidate as a potential blockbuster and an oral alternative to injectable biologics, noting ongoing trials in additional autoimmune indications and a head‑to‑head study versus a competing oral agent. Detailed safety and full data will be presented at a forthcoming medical meeting.